Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Baxter gets exclusive rights to Merrimack's late-stage pancreatic cancer candidate MM398

Executive Summary

Merrimack Pharmaceuticals Inc. (oncology drug development) granted Baxter International Inc. exclusive worldwide rights to sell its MM398 for patients with pancreatic cancer who have already been treated with gemcitabine. The deal excludes the US, where Merrimack retains rights, and Taiwan, where PharmaEngine already holds a license.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Liposomes
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies